The new clinical data on Bluebird's gene therapy are contained in a just-released abstract ahead of next month's American Society of Hematology annual meeting.
New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.
The new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
Aegerion Pharmaceuticals is spending $325 million, or almost all of its cash, to purchase a recently approved, orphan-disease drug from AstraZeneca.
Investors are selling Celldex today because of concerns the changes made to the METRIC study of CDX-011 introduce more risk
Not everyone is convinced that the new Sanofi CEO will remain committed to MannKind and its inhaled insulin Afrezza.
Briefing documents for Thursday's FDA advisory panel reviewing Rockwell Medical's RMTI Triferic iron replacement therapy were posted to the agency's web site this morning.
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The accusations of cocaine use and having sex with someone else's wife are the least of Marc Beer's problems. Aegerion Pharmaceuticals, the company he runs as CEO, is falling apart.